OncoKB Therapeutic Levels of Evidence

FDA-recognized biomarker predictive of response to an FDAapproved drug in this indication 2A Standard care biomarker predictive of response to an FDAapproved drug in this indication* **2B** Standard care biomarker predictive of response to an FDAapproved drug in another indication, but not standard care in this indication **3A** Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication 3B Compelling clinical evidence supports the biomarker as being predictive of response to a drug in another indication **Compelling biological evidence** supports the biomarker as being predictive of response to a drug Standard care biomarker predictive of resistance to an FDA-approved drug in this indication **R1**

Standard Therapeutic Implications

*Includes biomarkers
that are recommended
as standard care
by the NCCN or
other expert panels
but not necessarily
FDA-recognized
for a particular
indication

Investigational
Therapeutic
Implications
possibly directed
to clinical trials

Hypothetical Therapeutic Implications

based on preliminary, nonclinical data

Compelling clinical evidence supports the biomarker as being predictive of **resistance** to a drug

Standard Therapeutic Implications

Investigational Resistance Implications

based on clinical data



R2